Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sarah Gheuens Sells 1,489 Shares of Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Sarah Gheuens sold 1,489 shares of the company’s stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $37.53, for a total transaction of $55,882.17. Following the completion of the sale, the insider owned 54,645 shares of the company’s stock, valued at approximately $2,050,826.85. The trade was a 2.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sarah Gheuens also recently made the following trade(s):

• On Thursday, October 22nd, Sarah Gheuens sold 500 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $37.52, for a total value of $18,760.00.
• On Tuesday, August 4th, Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $30.48, for a total transaction of $914,400.00.

Agios Pharmaceuticals Stock Performance

AGIO traded down $0.19 during midday trading on Friday, reaching $37.00. The company had a trading volume of 920,048 shares, compared to its average volume of 1,059,158. The stock has a market cap of $2.21 billion, a PE ratio of -5.28 and a beta of 0.63. Agios Pharmaceuticals, Inc. has a 12-month low of $22.24 and a 12-month high of $46.00. The business has a 50-day moving average price of $33.34 and a two-hundred day moving average price of $32.76.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.65) by ($0.04). The firm had revenue of $44.75 million for the quarter, compared to the consensus estimate of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. On average, research analysts anticipate that Agios Pharmaceuticals, Inc. will post -5.83 earnings per share for the current year.

Institutional Trading of Agios Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in AGIO. Inspire Investing LLC lifted its holdings in Agios Pharmaceuticals by 4.7% during the 3rd quarter. Inspire Investing LLC now owns 19,130 shares of the biopharmaceutical company’s stock worth $636,000 after purchasing an additional 861 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in Agios Pharmaceuticals by 1,714.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,886,412 shares of the biopharmaceutical company’s stock worth $62,723,000 after purchasing an additional 1,782,457 shares during the period. Tidal Investments LLC grew its holdings in Agios Pharmaceuticals by 12.0% during the 2nd quarter. Tidal Investments LLC now owns 16,100 shares of the biopharmaceutical company’s stock valued at $597,000 after buying an additional 1,724 shares in the last quarter. Engineers Gate Manager LP grew its holdings in Agios Pharmaceuticals by 86.4% during the 2nd quarter. Engineers Gate Manager LP now owns 53,912 shares of the biopharmaceutical company’s stock valued at $2,001,000 after buying an additional 24,992 shares in the last quarter. Finally, Integrated Wealth Concepts LLC purchased a new position in Agios Pharmaceuticals during the 2nd quarter valued at about $47,000.

Analyst Ratings Changes

AGIO has been the subject of several recent research reports. Bank of America lifted their price objective on Agios Pharmaceuticals from $46.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, September 21st. JPMorgan Chase & Co. upped their price objective on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a “neutral” rating in a report on Friday, August 7th. Citigroup increased their target price on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Truist Financial reduced their target price on shares of Agios Pharmaceuticals from $39.00 to $37.00 and set a “buy” rating for the company in a research note on Wednesday, October 7th. Finally, HC Wainwright boosted their price target on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $41.50.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.